Cardiff Oncology's Q2 Net Loss Widens to $14.1M Amid R&D Spend

TL;DR

**CRDF is burning cash fast; expect more dilution or a major clinical win to keep it afloat.**

AI Summary

Cardiff Oncology, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company's net loss for the three months ended June 30, 2025, was $14.1 million, a 16.5% increase from the $12.1 million net loss for the same period in 2024. For the six months ended June 30, 2025, the net loss was $28.1 million, up 15.2% from $24.4 million in 2024. Research and development expenses increased to $10.9 million for the three months ended June 30, 2025, from $9.4 million in 2024, primarily due to higher clinical trial costs. Selling, general, and administrative expenses also rose to $3.2 million from $2.7 million in the prior year's quarter. The company's cash and cash equivalents, along with marketable securities, totaled $78.9 million as of June 30, 2025, down from $107.8 million at December 31, 2024, indicating a significant burn rate. The strategic outlook remains focused on advancing its clinical pipeline, particularly its lead drug candidate, onvansertib.

Why It Matters

Cardiff Oncology's widening net loss and significant cash burn rate are critical for investors, signaling continued reliance on external financing or strategic partnerships to fund its clinical trials. For employees, the company's financial health directly impacts job security and future growth opportunities. Customers, primarily future patients, depend on the successful and timely development of onvansertib, which is directly tied to the company's ability to sustain its R&D efforts. In the competitive oncology market, Cardiff's ability to manage its cash and advance its pipeline efficiently will determine its long-term viability against larger, better-funded pharmaceutical companies.

Risk Assessment

Risk Level: high — The company reported a net loss of $14.1 million for Q2 2025 and a cash balance of $78.9 million as of June 30, 2025, down from $107.8 million at December 31, 2024. This significant cash burn, coupled with no revenue, indicates a high risk of future dilution or liquidity issues if clinical milestones are not met.

Analyst Insight

Investors should monitor Cardiff Oncology's clinical trial progress for onvansertib closely, as positive data could significantly impact the stock. Given the high cash burn, consider the potential for future equity offerings and their dilutive effects before investing.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$14.1M

eps

N/A

gross Margin

N/A

cash Position

$78.9M

revenue Growth

0%

Revenue Breakdown

Key Numbers

• $14.1M — Net Loss (Increased by 16.5% from $12.1M in Q2 2024)
• $10.9M — Research and Development Expenses (Increased from $9.4M in Q2 2024, reflecting higher clinical trial costs)
• $78.9M — Cash and Marketable Securities (Decreased from $107.8M at December 31, 2024, indicating significant cash burn)
• 0% — Revenue Growth (No revenue reported for Q2 2025, consistent with pre-commercial stage)
• 15.2% — Six-Month Net Loss Increase (Net loss for six months ended June 30, 2025, rose to $28.1M from $24.4M in 2024)

Key Players & Entities

• Cardiff Oncology, Inc. (company) — filer of the 10-Q
• $14.1 million (dollar_amount) — net loss for Q2 2025
• $12.1 million (dollar_amount) — net loss for Q2 2024
• $28.1 million (dollar_amount) — net loss for six months ended June 30, 2025
• $24.4 million (dollar_amount) — net loss for six months ended June 30, 2024
• $10.9 million (dollar_amount) — R&D expenses for Q2 2025
• $9.4 million (dollar_amount) — R&D expenses for Q2 2024
• $3.2 million (dollar_amount) — SG&A expenses for Q2 2025
• $2.7 million (dollar_amount) — SG&A expenses for Q2 2024
• $78.9 million (dollar_amount) — cash and marketable securities as of June 30, 2025

FAQ

Risk Factors

• Significant Cash Burn Rate [high — financial]: Cardiff Oncology's cash and marketable securities decreased from $107.8 million at December 31, 2024, to $78.9 million as of June 30, 2025. This represents a burn of $28.9 million in six months, highlighting the need for continued funding to support operations and clinical development.
• Clinical Trial Execution and Costs [high — operational]: Research and development expenses increased to $10.9 million for the three months ended June 30, 2025, from $9.4 million in the prior year's quarter, primarily due to higher clinical trial costs. Delays or increased costs in ongoing or future trials could significantly impact the company's timeline and financial resources.
• Drug Approval and Market Access [high — regulatory]: As a pre-commercial company, Cardiff Oncology's success is contingent on the successful development and regulatory approval of its drug candidates, particularly onvansertib. Failure to achieve these milestones or secure market access could render the company's investments in R&D unrecoverable.
• Increasing Net Losses [medium — financial]: The company reported a net loss of $14.1 million for the three months ended June 30, 2025, a 16.5% increase from $12.1 million in the same period of 2024. The six-month net loss also increased by 15.2% to $28.1 million. Continued losses without corresponding revenue growth put pressure on cash reserves.
• Competition in Oncology Market [medium — market]: The oncology drug market is highly competitive, with numerous established and emerging biopharmaceutical companies developing novel therapies. Cardiff Oncology faces competition from companies with potentially more advanced pipelines or greater financial resources.

Industry Context

Cardiff Oncology operates in the highly competitive biopharmaceutical sector, specifically focusing on oncology. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Companies like Cardiff Oncology are driven by the potential for breakthrough therapies, but face intense competition from both large pharmaceutical firms and smaller biotech companies vying for market share and investor capital.

Regulatory Implications

As a clinical-stage biopharmaceutical company, Cardiff Oncology is subject to rigorous oversight by regulatory bodies such as the FDA. The success of its lead candidate, onvansertib, hinges on meeting clinical trial endpoints and obtaining regulatory approval. Any delays, adverse findings, or changes in regulatory requirements could significantly impact the company's development timeline and commercialization prospects.

What Investors Should Do

1. Monitor clinical trial progress and data readouts for onvansertib.
2. Assess the company's cash runway and future financing needs.
3. Evaluate the competitive landscape and market potential for onvansertib.

Glossary

Pre-commercial stage

A phase in a company's lifecycle where it has not yet begun generating revenue from product sales, typically focusing on research, development, and clinical trials. (Explains why Cardiff Oncology has no reported revenue and is investing heavily in R&D.)

Onvansertib

Cardiff Oncology's lead drug candidate, currently in clinical development for various cancer indications. (The primary focus of the company's R&D efforts and future revenue potential.)

Cash burn rate

The rate at which a company is spending its cash reserves, particularly when it is not generating sufficient revenue to cover its expenses. (Indicates the speed at which the company is depleting its cash, highlighting the urgency for funding or profitability.)

Research and Development Expenses

Costs incurred by a company in the process of developing new products or improving existing ones, including clinical trial costs, salaries for researchers, and lab supplies. (A significant expense for Cardiff Oncology, directly related to advancing its drug pipeline.)

Selling, General, and Administrative Expenses (SG&A)

Costs associated with marketing, sales, and the general operations of a business, excluding direct production costs. (Represents operational overhead for Cardiff Oncology, which is increasing alongside R&D.)

Year-Over-Year Comparison

Cardiff Oncology's Q2 2025 filing shows a continued increase in net losses, with a 16.5% rise in the quarterly loss to $14.1 million and a 15.2% increase in the six-month loss to $28.1 million, compared to the prior year periods. This is driven by a 17% increase in R&D expenses, primarily due to higher clinical trial costs, and a rise in SG&A. The company's cash position has also declined significantly, from $107.8 million at year-end 2024 to $78.9 million, indicating an accelerated cash burn. No revenue is being generated, consistent with its pre-commercial status.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on July 29, 2025 regarding Cardiff Oncology, Inc. (CRDF).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR